Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
We examined the effect of berberine, a major component with anti-fungal properties contained in Coptidis Rhizoma and Phellodendri Cortex, on the lymph node metastasis of murine lung cancer. Oral administration of berberine for 14 days significantly inhibited the spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma (LLC) into the lung parenchyma in a dose-dependent manner, but did not affect the tumor growth at the implantation site of the lung. Combined treatment with berberine and an anti-cancer drug, CPT-11, resulted in a marked inhibition of tumor growth at the implantation site and of lymphatic metastasis, as compared with either treatment alone. Anti-activator protein-1 (anti-AP-1) transcriptional activity of non-cytotoxic concentrations of berberine caused the inhibition of the invasiveness of LLC cells through the repression of expression of urokinase-type plasminogen activator (u-PA).
Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-0194, Toyama, Japan.
N
N
Mitani
K
K
Murakami
T
T
Yamaura
T
T
Ikeda
I
I
Saiki
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001599:Berberine / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000517:prevention & control / Q000556:secondary*; D004195:Disease Models, Animal; D005260:Female; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000473:pathology* / Q000517:prevention & control; D008207:Lymphatic Metastasis; D008479:Mediastinal Neoplasms / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D009368:Neoplasm Transplantation; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors
D018808:Transcription Factor AP-1; D001599:Berberine; D000077146:Irinotecan; D002166:Camptothecin